Merck’s Gefapixant: FDA Questions Whether Small Reduction In Chronic Cough Is Clinically Meaningful

 
• By Brenda Sandburg

Gefapixant 45 mg had a 15% to 17% relative reduction in 24-hour cough frequency compared to placebo from baseline to week 24 or week 12. Advisory committee to vote on whether this decrease along with results from patient-reported outcomes demonstrate a clinically meaningful benefit.

Cough
FDA panel to consider clinical data on Merck's drug for treatment of chronic cough • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers